Skip to main content

Table 2 Content of information PIs provided with local and imported anti-hypertensive medications

From: Comparative analysis of package inserts of local and imported antihypertensive medications in Palestine

Criteria

A

N = 6 (40% of local PIs)

B

N = 4

(26.67% of local PIs)

C

N = 3

(20% of local PIs)

D

N = 2 (13.33% of local PIs)

Total scores of Local Products N = 15 (42.86% of total PIs)

Total scores of Imported Products N = 20 (57.14% of total PIs)

Total

N = 35 (100%)

Brand name

6 (100%)

4 (100)

3 (100)

2 (100)

15 (100)

20 (100)

35 (100)

Active ingredient

6 (100)

4 (100)

3 (100)

2 (100)

15 (100)

20 (100)

35 (100)

Inactive ingredients (excipients)

0 (0)

0 (0)

0 (0)

1 (50)

1 (6.6)

20 (100)

21 (60)

Therapeutic class

2 (33.3)

0 (0)

2 (66.6)

2 (100)

6 (40)

19 (95)

25 (71.4)

Mechanism of action

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

6 (30)

6 (17.1)

Indications

6 (100)

4 (100)

3 (100)

2 (100)

15 (100)

20 (100)

35 (100)

Drug dose

0 (0)

1 (25)

1 (33.3)

0 (0)

2 (13.3)

7 (35)

9 (25.7)

Duration of using

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

1 (5)

1 (2.8)

Missing dose

6 (100)

2 (50)

2 (66.6)

2 (100)

12 (80)

17 (85)

29 (82.8)

Maximum dose

0 (0)

1 (25)

1 (33.3)

0 (0)

2 (13.3)

2 (10)

4 (11.4)

Directions for use

6 (100)

4 (100)

3 (100)

2 (100)

15 (100)

20 (100)

35 (100)

Overdose and management

6 (100)

2 (50)

3 (100)

2 (100)

13 (86.6)

20 (100)

33 (94.2)

Warning and precautions

6 (100)

4 (100)

3 (100)

2 (100)

15 (100)

19 (95)

34 (97.1)

Effect on ability to drive and use machines

0 (0)

1 (25)

1 (33.3)

1 (50)

3 (20)

20 (100)

23 (65.7)

Contraindications

6 (100)

2 (50)

3 (100)

2 (100)

13 (86.6)

20 (100)

33 (94.2)

Adverse drug reactions

6 (100)

4 (100)

3 (100)

2 (100)

15 (100)

20 (100)

35 (100)

Drug-drug interactions

6 (100)

4 (100)

3 (100)

2 (100)

15 (100)

20 (100)

35 (100)

Drug-food interactions

1 (16.6)

1 (25)

1 (33.3)

1 (50)

4 (26.6)

19 (95)

23 (65.7)

Pregnancy considerations

6 (100)

4 (100)

3 (100)

2 (100)

15 (100)

20 (100)

35 (100)

Lactation considerations

6 (100)

4 (100)

3 (100)

2 (100)

15 (100)

20 (100)

35 (100)

Pediatric considerations

4 (66.6)

3 (75)

3 (100)

2 (100)

12 (80)

20 (100)

32 (91.4)

Geriatric considerations

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

11 (55)

11 (31.4)

Possibility of tablet splitting

0 (0)

1 (25)

0 (0)

1 (50)

2 (13.3)

15 (75)

17 (48.5)

Possibility of crushing and mixing with food or beverages

4 (66.6)

3 (75)

1 (33.3)

1 (50)

9 (60)

15 (75)

24 (68.5)

Instructions to convert tablets or capsules into liquid forms

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

Pharmacokinetic information

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

2 (10)

2 (5.7)

Shelf life

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

0 (0)

Storage

6 (100)

4 (100)

3 (100)

2 (100)

15 (100)

20 (100)

35 (100)

Name and address of manufacturers/distributors

6 (100)

4 (100)

3 (100)

2 (100)

15 (100)

19 (95)

34 (97.1)

Date of last revision

0 (0)

0 (0)

0 (0)

1 (50)

1 (6.6)

14 (70)

15 (42.8)

Sources of information

5 (83.3)

2 (50)

1 (33.3)

0 (0)

8 (53.3)

0 (0)

8 (22.8)